The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure

Journal of Cardiac Failure

Volumn 12, Issue 2, 2006, Pages 122-127

  Kotlyar, Eugene ^a   Vita, Joseph A ^a   Winter, Michael R ^b   Awtry, Eric H ^a   Siwik, Deborah A ^b   Keaney Jr , John F ^a   Sawyer, Douglas B ^a   Cupples, L Adrienne ^b   Colucci, Wilson S ^a,b   Sam, Flora ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Aldosterone; Heart failure; Inflammation; Matrix; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; OSTEOPONTIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGE; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; GENDER; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYOCARDITIS; OXIDATIVE STRESS; PRIORITY JOURNAL; RACE; SMOKING;

ALDOSTERONE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DINOPROST; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OSTEOPONTIN; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROCOLLAGEN; SIALOGLYCOPROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33644773392     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2005.08.005     Document Type: Article

References (48)

1. K. Swedberg, P. Eneroth, J. Kjekshus, and L. Wilhelmsen Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Consensus trial study group Circulation 82 1990 1730 1736
2. N.J. Brown Eplerenone: cardiovascular protection Circulation 107 2003 2512 2518
3. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, and A. Perez The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N Engl J Med 341 1999 709 717
4. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
5. Y. Sun, J. Zhang, L. Lu, S.S. Chen, M.T. Quinn, and K.T. Weber Aldosterone-induced inflammation in the rat heart: role of oxidative stress Am J Pathol 161 2002 1773 1781
6. B. Schwartzkopff, M. Fassbach, B. Pelzer, M. Brehm, and B.E. Strauer Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy Eur J Heart Fail 4 2002 439 444
7. F. Zannad, F. Alla, B. Dousset, A. Perez, and B. Pitt Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators Circulation 102 2000 2700 2706
8. C.G. Brilla, and K.T. Weber Reactive and reparative myocardial fibrosis in arterial hypertension in the rat Cardiovasc Res 26 1992 671 677
9. Z. Mallat, I. Philip, M. Lebret, D. Chatel, J. Maclouf, and A. Tedgui Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure Circulation 97 1998 1536 1539
10. G. Torre-Amione, S. Kapadia, C. Benedict, H. Oral, J.B. Young, and D.L. Mann Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD) J Am Coll Cardiol 27 1996 1201 1206
11. H. Lum, and K.A. Roebuck Oxidant stress and endothelial cell dysfunction Am J Physiol Cell Physiol 280 2001 C719 C741
12. E.M. Mervaala, D.N. Muller, J.K. Park, F. Schmidt, M. Lohn, and V. Breu Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension Hypertension 33 1999 389 395
13. B.R. Clapp, A.D. Hingorani, R.K. Kharbanda, V. Mohamed-Ali, J.W. Stephens, and P. Vallance Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress Cardiovasc Res 64 2004 172 178
14. D.A. Siwik, and W.S. Colucci Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium Heart Fail Rev 9 2004 43 51
15. D.J. Sahn, A. Demaria, J. Kisslo, and A. Weyman Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements Circulation 58 1978 1072 1083
16. N.B. Schiller, P.M. Shah, M. Crawford, A. Demaria, R. Devereux, and H. Feigenbaum Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms J Am Soc Echocardiogr 2 1989 358 367
17. R.B. Devereux, D.R. Alonso, E.M. Lutas, G.J. Gottlieb, E. Campo, and I. Sachs Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings Am J Cardiol 57 1986 450 458
18. D.N. Granger, T. Vowinkel, and T. Petnehazy Modulation of the inflammatory response in cardiovascular disease Hypertension 43 2004 924 931
19. J.D. Morrow Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans Arterioscler Thromb Vasc Biol 25 2005 279 286
20. J.L. Cracowski, F. Tremel, C. Marpeau, J.P. Baguet, F. Stanke-Labesque, and J.M. Mallion Increased formation of F(2)-isoprostanes in patients with severe heart failure Heart 84 2000 439 440
21. D. Hasper, M. Hummel, F.X. Kleber, I. Reindl, and H.D. Volk Systemic inflammation in patients with heart failure Eur Heart J 19 1998 761 765
22. D.R. Pimentel, J.K. Amin, L. Xiao, T. Miller, J. Viereck, and J. Oliver-Krasinski Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes Circ Res 89 2001 453 460
23. J.K. Amin, L. Xiao, D.R. Pimental, P.J. Pagano, K. Singh, and D.B. Sawyer Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes J Mol Cell Cardiol 33 2001 131 139
24. L. Xiao, D.R. Pimental, J.K. Amin, K. Singh, D.B. Sawyer, and W.S. Colucci MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes J Mol Cell Cardiol 33 2001 779 787
25. S.H. Kwon, D.R. Pimentel, A. Remondino, D.B. Sawyer, and W.S. Colucci H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways J Mol Cell Cardiol 35 2003 615 621
26. P. Aukrust, T. Ueland, E. Lien, K. Bendtzen, F. Muller, and A.K. Andreassen Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 83 1999 376 382
27. G.M. Kuster, E. Kotlyar, M.K. Rude, D.A. Siwik, R. Liao, and W.S. Colucci Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload Circulation 111 2005 420 427
28. R. Rocha, A.E. Rudolph, G.E. Frierdich, D.A. Nachowiak, B.K. Kekec, and E.A. Blomme Aldosterone induces a vascular inflammatory phenotype in the rat heart Am J Physiol Heart Circ Physiol 283 2002 H1802 H1810
29. F. Sam, Z. Xie, H. Ooi, D.L. Kerstetter, W.S. Colucci, and M. Singh Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion Am J Hypertens 17 2004 188 193
30. Y. Matsui, N. Jia, H. Okamoto, S. Kon, H. Onozuka, and M. Akino Role of osteopontin in cardiac fibrosis and remodeling in angiotensin ii-induced cardiac hypertrophy Hypertension 43 2004 1195 1201
31. K.A. Youker, H.K. Hawkins, G.L. Kukielka, J.L. Perrard, L.H. Michael, and C.M. Ballantyne Molecular evidence for induction of intracellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart Circulation 89 1994 2736 2746
32. P.M. Ridker, M.J. Stampfer, and N. Rifai Novel risk factors for systemic atherosclerosis: a comparison of c-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease JAMA 285 2001 2481 2485
33. W.H. Yin, J.W. Chen, H.L. Jen, M.C. Chiang, W.P. Huang, and A.N. Feng Independent prognostic value of elevated high-sensitivity c-reactive protein in chronic heart failure Am Heart J 147 2004 931 938
34. D.T. Denhardt, M. Noda, A.W. O'Regan, D. Pavlin, and J.S. Berman Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival J Clin Invest 107 2001 1055 1061
35. M. Mazzali, T. Kipari, V. Ophascharoensuk, J.A. Wesson, R. Johnson, and J. Hughes Osteopontin - a molecule for all seasons QJM 95 2002 3 13
36. C.G. Brilla, G. Zhou, L. Matsubara, and K.T. Weber Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin ii and aldosterone J Mol Cell Cardiol 26 1994 809 820
37. J.B. Laursen, S. Rajagopalan, Z. Galis, M. Tarpey, B.A. Freeman, and D.G. Harrison Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension Circulation 95 1997 588 593
38. R.J. Gryglewski, R.M. Palmer, and S. Moncada Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor Nature 320 1986 454 456
39. C.G. Schnackenberg, and C.S. Wilcox Two-week administration of tempol attenuates both hypertension and renal excretion of 8-iso prostaglandin F2alpha Hypertension 33 1999 424 428
40. K. Kameda, T. Matsunaga, N. Abe, H. Hanada, H. Ishizaka, and H. Ono Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling Eur Heart J 24 2003 2180 2185
41. T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, and T. Tsutsui Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure J Am Coll Cardiol 36 2000 838 844
42. A. Benetos, P. Lacolley, and M.E. Safar Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats Arterioscler Thromb Vasc Biol 17 1997 1152 1156
43. M.M. Lindsay, P. Maxwell, and F.G. Dunn TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension Hypertension 40 2002 136 141
44. E.E. Creemers, J.N. Davis, A.M. Parkhurst, P. Leenders, K.B. Dowdy, and E. Hapke Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice Am J Physiol Heart Circ Physiol 284 2003 H364 H371
45. J. Sundstrom, J.C. Evans, E.J. Benjamin, D. Levy, M.G. Larson, and D.B. Sawyer Relations of plasma total timp-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study Eur Heart J 25 2004 1509 1516
46. G.H. Williams, J.P. Cain, R.G. Dluhy, and R.H. Underwood Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading J Clin Invest 51 1972 1731 1742
47. M.G. Nicholls, E.A. Espiner, and R.A. Donald Aldosterone and renin-angiotensin responses to stimuli in patients with treated congestive heart failure J Lab Clin Med 87 1976 1005 1015
48. R.S. Vasan, J.C. Evans, E.J. Benjamin, D. Levy, M.G. Larson, and J. Sundstrom Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study Hypertension 43 2004 957 962